TY - GEN
T1 - pADR
T2 - 32nd ACM International Conference on Information and Knowledge Management, CIKM 2023
AU - Luo, Junyu
AU - Qian, Cheng
AU - Wang, Xiaochen
AU - Glass, Lucas
AU - Ma, Fenglong
N1 - Publisher Copyright:
© 2023 Copyright held by the owner/author(s). Publication rights licensed to ACM.
PY - 2023/10/21
Y1 - 2023/10/21
N2 - Predicting adverse drug reactions (ADRs) of drugs is one of the most critical steps in drug development. By pre-estimating the adverse reactions, researchers and drug development companies can greatly prevent the potential ADR risks and tragedies. However, the current ADR prediction methods suffer from several limitations. First, the prediction results are based on pure drug-related information, which makes them impossible to be directly applied for the personalized ADR prediction task. The lack of personalization of models also makes rare adverse events hard to be predicted. Therefore, it is of great interest to develop a new personalized ADR prediction method by introducing additional sources, e.g., patient health records. However, few methods have tried to use additional sources. In the meantime, the variety of different source formats and structures makes this task more challenging. To address the above challenges, we propose a novel personalized multi-sourcedbased drug adverse reaction prediction model named pADR. pADR first works on every single source to transform them into proper representations. Next, a hierarchical multi-sourced Transformer is designed to automatically model the interactions between different sources and fuse them together for the final adverse event prediction. Experimental results on a new multi-sourced ADR prediction dataset show that pADR outperforms state-of-the-art drug-based baselines. Moreover, the case and ablation studies also illustrate the effectiveness of our proposed fusion strategies and the reasonableness of each module design.
AB - Predicting adverse drug reactions (ADRs) of drugs is one of the most critical steps in drug development. By pre-estimating the adverse reactions, researchers and drug development companies can greatly prevent the potential ADR risks and tragedies. However, the current ADR prediction methods suffer from several limitations. First, the prediction results are based on pure drug-related information, which makes them impossible to be directly applied for the personalized ADR prediction task. The lack of personalization of models also makes rare adverse events hard to be predicted. Therefore, it is of great interest to develop a new personalized ADR prediction method by introducing additional sources, e.g., patient health records. However, few methods have tried to use additional sources. In the meantime, the variety of different source formats and structures makes this task more challenging. To address the above challenges, we propose a novel personalized multi-sourcedbased drug adverse reaction prediction model named pADR. pADR first works on every single source to transform them into proper representations. Next, a hierarchical multi-sourced Transformer is designed to automatically model the interactions between different sources and fuse them together for the final adverse event prediction. Experimental results on a new multi-sourced ADR prediction dataset show that pADR outperforms state-of-the-art drug-based baselines. Moreover, the case and ablation studies also illustrate the effectiveness of our proposed fusion strategies and the reasonableness of each module design.
UR - http://www.scopus.com/inward/record.url?scp=85178147246&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85178147246&partnerID=8YFLogxK
U2 - 10.1145/3583780.3615490
DO - 10.1145/3583780.3615490
M3 - Conference contribution
C2 - 38601743
AN - SCOPUS:85178147246
T3 - International Conference on Information and Knowledge Management, Proceedings
SP - 4724
EP - 4730
BT - CIKM 2023 - Proceedings of the 32nd ACM International Conference on Information and Knowledge Management
PB - Association for Computing Machinery
Y2 - 21 October 2023 through 25 October 2023
ER -